Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CBD for Joint Pain of Adjuvant Endocrine Therapy in Early Breast Cancer
NCT06787118Phase 3Not yet recruiting
- Sponsor
- Gustave Roussy
- Start
- Dec 2025
- Primary completion
- May 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of cannabidiol in Musculoskeletal pain (2 arms), sponsored by Gustave Roussy. Primary endpoint: Brief Pain Inventory - Short Form Interference score at 37 weeks. Planned start Dec 2025; status: not yet recruiting.
02
Drugs
cannabidiol
03
Conditions
Musculoskeletal pain
Beyond the preview
Go deeper on NCT06787118.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06787118.